What is it?
What phenibut is
1Phenibut is a synthetic analogue of gamma-aminobutyric acid (GABA), a chemical messenger involved in inhibitory signaling. It is psychoactive and appears in both hydrochloride salt and free amino acid product labels.
Evidence snapshot
6Older regional patient reports and pharmacology studies provide limited evidence. They do not establish meaningful cognitive enhancement in healthy adults, a reliable consumer dosing regimen, or a safe repeated-use cycle.
Names, aliases and forms
Mechanisms of action
GABA-B-related pharmacology
6Phenibut is structurally related to GABA and is commonly discussed in relation to GABA-B activity and central nervous system effects. This mechanistic framing helps explain sedation and dependence risk, but does not establish a cognitive-performance benefit.
Alpha-2-delta calcium-channel evidence
12R-phenibut has been reported to bind the alpha-2-delta subunit of voltage-dependent calcium channels and to show gabapentin-like effects in preclinical models. This supports a more precise pharmacology description, but it remains mechanistic/preclinical evidence rather than a consumer benefit claim.
Potential effects and evidence map
Older regional clinical reports concern patient populations, not healthy-adult cognitive enhancement. Modern human evidence chiefly characterizes tolerability, intoxication and withdrawal. Pharmacology and animal findings do not establish an everyday nootropic benefit.
Older regional patient literature describes calming effects, but it does not establish their magnitude in healthy adults or the benefit-risk balance of consumer use.
Sleep-related use appears in older/regional literature, but modern supplement-use evidence is limited and the same sedative effects create impairment risk.
Mood or stress-related claims are not strongly established for consumer nootropic use; available human support is older, regional, and context-specific.
Anecdotal social-ease claims are common online, but reliable human evidence for this public-use claim is absent or too indirect.
There is no reliable evidence signal that phenibut supports focus or attention in healthy consumers.
Memory and learning claims are not supported by strong modern human evidence for consumer nootropic use.
Typical dosages and timing
The 2020 safety review describes this oral range in medical use. Its clinical reports concern patients and do not define a validated nootropic regimen for healthy adults. Product label amounts and self-reported recreational exposure are different evidence contexts.
Timing & effect horizon
The WHO ECDD report repeats a 5.3-hour plasma The time for blood levels to fall by half during the final elimination phase.Source after an oral dose but notes that the underlying primary human data could not be examined. Its oral onset and subjective duration estimates came from recreational-user reports. Neither establishes a reliable effect duration, repeat-dose interval or recommended cycle.
Safety, side effects and risk profile
Somnolence was reported in 1.89% of patients in a review of clinical reports. Poison-center exposures separately document reduced consciousness, respiratory depression and coma; those reports do not estimate incidence at medical doses.
Repeated use can cause tolerance and dependence. Withdrawal case literature documents severe agitation, psychosis, delirium and seizures; almost all withdrawal cases in the 2023 review involved daily use, often with other substances. Frequency at medical doses is unresolved.
Alcohol, opioids, benzodiazepines and other sedating drugs can add impairment and respiratory-depression hazards. Many severe reported cases involved multiple substances; risks differ between individual medications.
As checked in October 2026, the U.S. FDA states that phenibut is not a dietary ingredient; supplements declaring it as one are misbranded. This is a U.S. marketing determination, separate from possession and other jurisdictions.
Agitation and insomnia are documented particularly in intoxication or withdrawal, rather than as established frequent reactions at medical doses.
Nausea and other gastrointestinal complaints appear in exposure and case literature.
Dizziness and neurologic symptoms are reported in poison-center and case literature.
Tachycardia and blood-pressure related concerns appear in exposure reports, especially in adverse-use contexts.
Pregnancy and lactation safety are inadequately characterized; no numerical risk estimate is supported for these populations.
Healthy-adult benefit and long-term safety remain inadequately characterized. Separate product testing found widely varying phenibut content in a small sample; this does not measure every current product.
U.S. poison centers recorded 1,320 phenibut exposures in 2009-2019, including coma in 6.2%, major effects in 12.6%, and three deaths. Major effects also occurred among single-agent reports. Most calls came from healthcare facilities, and co-exposure was common; these are selected exposure reports, not incidence rates among typical users.
Tolerance and physical dependence are documented with repeated use. The 2023 case review found daily use in 95.7% of withdrawal cases; other substance use was common across the full case set. Severe presentations included agitation, psychosis and seizures. Cases were often reversible with clinical care but sometimes involved prolonged admission. Published cases cannot establish a safe dose, use frequency or withdrawal self-management protocol.
Drowsiness, confusion and reduced consciousness can impair driving and machinery operation. Poison-center reports include respiratory depression and coma in adverse exposures.
Interactions and cautions
Alcohol, benzodiazepines, opioids, sleep aids and other sedating medicines can add central nervous system depression, including impairment and breathing hazards. Combination-use case reports do not quantify the interaction risk of each drug pair.
Risks with psychiatric, neurologic, pain or seizure medicines depend on the specific agent and exposure. Pregnancy and lactation data are inadequate. The withdrawal literature describes clinical management, not a validated self-directed taper or substitution plan.
Legal and regulatory status
As checked on 19 October 2026, the U.S. FDA states that phenibut does not meet the FD&C Act definition of a dietary ingredient. Dietary supplements declaring it as a dietary ingredient are considered misbranded. This statement concerns U.S. product marketing.
The U.S. CDC report published in September 2020 described phenibut as legal to possess and not FDA-approved as a licensed pharmaceutical drug. That historical description does not establish current state, local, import or product-specific rules in 2026.
The WHO ECDD 2021 report describes phenibut medicine use in Russia and Latvia and differing national controls elsewhere. This historical medical-use context is not current approval for every product or permission to import it. Local medicine, food-supplement and controlled-substance rules require jurisdiction-specific checks.
How it compares
Hydrochloride salt and free amino acid labels describe different chemical forms. Compare the declared form and measured content before comparing price per gram or capsule; equal package weights do not establish identical phenibut exposure or clinical effects.
Practical buying and quality notes
- In a four-brand analysis, measured phenibut content after FDA warnings ranged from 21 to 1,164 mg per serving. This small historical sample shows why a serving, capsule or scoop is not a standardized exposure; it does not establish the content of products listed today.9
- In the United States, the FDA position checked in October 2026 concerns dietary-supplement marketing. A merchant listing or overseas medicine brand does not establish U.S. market authorization or local import eligibility.2
- Price per capsule needs the stated milligrams per capsule; powder prices need the stated form and net quantity. Keep tablets, capsules and bulk powder separate when comparing listed unit prices, and include delivery charges and currency. A batch certificate should identify the same form and lot and report assay, not only a generic purity claim.9
- The four-brand product study found phenibut in more products and at higher quantities after the FDA warnings. Its narrow historical sample supports checking the actual batch and serving amount; it does not rank current vendors or prove that every listed product is mislabeled.9
FAQ
Is phenibut a dietary supplement in the U.S.?
2As checked in October 2026, the U.S. FDA excludes phenibut from the statutory definition of a dietary ingredient. A product being sold online does not change that dietary-supplement marketing determination.
How long do phenibut effects last, and is there a safe cycle?
11Controlled human data do not establish a reliable effect duration or a safe consumer cycle. Recreational reports and a weakly documented plasma half-life cannot determine repeat-dose timing. Repeated use can lead to tolerance and dependence, with potentially severe withdrawal.
Does phenibut have strong nootropic evidence?
6No. Older/regional medical-use and pharmacology literature exists, but strong modern human evidence for general cognitive enhancement, focus, memory, or motivation in healthy consumers is not established.
What does the reported dosage range mean?
13It describes medical-dose context summarized in the safety review, rather than an established healthy-adult nootropic regimen. Trial populations, monitored use and product quality differ from unsupervised online-product use.
References
- PubChem. Phenibut (CID 14113). National Library of Medicine.
- U.S. Food and Drug Administration. Phenibut in Dietary Supplements.
- U.S. Food and Drug Administration. FDA Acts on Dietary Supplements Containing DMHA and Phenibut. Content current as of 2019-04-29.
- Graves JM, Dilley JA, Kubsad S, Liebelt E. Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1227-1228.
- McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med. 2019;37(11):2066-2071.
- Penzak SR, Bulloch M. Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal. J Clin Pharmacol. 2024;64(6):652-671.
- Weleff J, Kovacevich A, Burson J, Nero N, Anand A. Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review. J Addict Med. 2023;17(4):407-417.
- Stewart C, et al. A Systematic Review of Phenibut Withdrawals. Cureus. 2024;16(9):e68775.
- Cohen PA, Ellison RR, Travis JC, Gaufberg SV, Gerona R. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila). 2022;60(4):486-488.
- Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7(4):471-481.
- WHO Expert Committee on Drug Dependence. Phenibut: Pre-Review Report. Forty-fourth meeting, 11-15 October 2021.
- Zvejniece L, Vavers E, Svalbe B, et al. R-phenibut binds to the alpha2-delta subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav. 2015;137:23-29.
- Kupats E, Vrublevska J, Zvejniece B, et al. Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports. Pharmacopsychiatry. 2020;53(5):201-208.